

Holdings Report

September 2023

Regnan Global Equity Impact Solutions Fund

ARSN: 645 981 853

Fund holdings (as at 30 September 2023)

Security ID	Security Name
BMF7DY4	Abcam PLC
BKF9D57	Afya Ltd
2520153	Agilent Technologies Inc
5468346	AIXTRON SE
BG0SJ42	Alfen N.V.
2045623	ANSYS Inc
BP8JT73	ATS Corp
BFMLGR4	Autolus Therapeutics PLC
6709099	Bank Rakyat Indonesia Persero Tbk PT
BDZRDG3	Befesa SA
5922961	Carl Zeiss Meditec AG
5119901	Duerr AG
2304227	Ecolab Inc
BK5GMG2	Hoffmann Green Cement Technologies SAS
6437947	Horiba Ltd
B608Z99	llika PLC
4512330	Lenzing AG
7333378	Lonza Group AG
BZ04921	Munters Group AB
BP6KMJ1	Novo Nordisk A/S
BYT16L4	Orsted AS
B95N910	PTC Inc
BYXS699	QIAGEN NV
BYZ2QP5	Sartorius Stedim Biotech
BNM0752	Stevanato Group SpA
B8P59C0	Syncona Limited
BPLXRG7	TOMRA Systems ASA
BF44466	Umicore SA
BDC5ST8	Valeo SE
B3P2CN8	Xylem Inc/NY
BJGV3C2	YDUQS Participacoes SA



The Regnan Global Equity Impact Solutions Fund has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See www.responsiblereturns.com.au for details.

CERTIFIED BY RIAA

The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

For more information please, contact your key account manager or visit regnan.com



This report has been prepared by Pendal Fund Services Limited (**PFSL**) ABN 13 161 249 332, AFSL No 431426 and the information contained within is current as at the date of this report. It is not to be published, or otherwise made available to any person other than the party to whom it is provided.

PFSL is the responsible entity of, and issuer of units in, the Fund offered in this report. A product disclosure statement (**PDS**) is available for the Fund and can be obtained by calling 1300 346 821 or visiting <u>www.pendalgroup.com</u>. The Target Market Determination (**TMD**) for the Fund is available at <u>www.pendalgroup.com/ddo</u>. You should obtain and consider the PDS and TMD before deciding whether to acquire, continue to hold or dispose of units in the Fund. An investment in the Fund is subject to investment risk, including possible delays in repayment of withdrawal proceeds and loss of income and principal invested.

This report is for general information purposes only, should not be considered as a comprehensive statement on any matter and should not be relied upon as such. It has been prepared without taking into account any recipient's personal objectives, financial situation or needs. Because of this, recipients should, before acting on this information, consider its appropriateness having regard to their individual objectives, financial situation and needs. This information is not to be regarded as a securities recommendation.

The information in this report may contain material provided by third parties, is given in good faith and has been derived from sources believed to be accurate as at its issue date. While such material is published with necessary permission, and while all reasonable care has been taken to ensure that the information in this report is complete and correct, to the maximum extent permitted by law neither PFSL nor any company in the Pendal group accepts any responsibility or liability for the accuracy or completeness of this information.